233 related articles for article (PubMed ID: 27149456)
1. Cost-Effectiveness of Eplerenone Compared to Usual Care in Patients With Chronic Heart Failure and NYHA Class II Symptoms, an Australian Perspective.
Ademi Z; Pasupathi K; Liew D
Medicine (Baltimore); 2016 May; 95(18):e3531. PubMed ID: 27149456
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of eplerenone in patients with chronic heart failure.
Ademi Z; Pasupathi K; Krum H; Liew D
Am J Cardiovasc Drugs; 2014 Jun; 14(3):209-16. PubMed ID: 24610254
[TBL] [Abstract][Full Text] [Related]
3. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
[TBL] [
